By Maitane Sardon
Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division.
Shares traded 4.7% higher on Friday at 11.17 euros, but they are down 28% over the year to date.
The Spanish pharmaceuticals company said total revenue reached 1.79 billion euros ($1.93 billion)in the third quarter, a 12.2% increase on a reported basis. The figure was 2.2% ahead of Visible Alpha consensus.
Adjusted earnings before interest, taxes, depreciation, and amortization rose 26.7% at constant currency to 462 million euros, driven by product mix, lower cost per liter and operational leverage, Grifols said.
The company said it is on track to reach full year revenue of more than 7 billion euros.
"This was a relatively clean set of results, with no negative surprises and perhaps a few positive ones," Berenberg analysts said in a note. "The ongoing bid situation creates a short-term risk for the shares, as should the Brookfield/Grifols family consortium fail to make an offer for the shares then it would be churlish not to expect some short-term share price weakness," they added.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
November 08, 2024 05:40 ET (10:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。